Bacterin Announces Updates on Executive Leadership Transition Plans

Company in final stages of identifying search firm; several candidates express interest

BELGRADE, Mont.–(BUSINESS WIRE)– Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of revolutionary bone graft material and coatings for medical applications, today announced that it is in the final stages of identifying a key executive search firm to assist with the identification of a new Chief Executive Officer. The Company has narrowed its selection to three search firms and noted that it expects to have selected a firm by the end of next week.

“It is business as usual here at Bacterin,” said Kent Swanson, Chairman of Bacterin International. “We have been pleased with the speed at which our board and management team – headed by interim Co-CEO’s, John Gandolfo, Chief Financial Officer, and Darrel Holmes, Chief Operating Officer – have diligently worked to align and stabilize the business as the result of our recent management transition and to retain a search firm for our new Chief Executive Officer position. Our business remains stable and our employees are now more optimistic about the prospects of the Company.”

The Company also announced solid progress with cost reduction measures designed to generate positive EBITDA.

Mr. Swanson further commented, “I am confident of the value proposition our products and services offers to the market place. The candidate for our Chief Executive Officer position will have an understanding of our product portfolio and will have a track record of developing markets in this evolving healthcare environment. This candidate will represent a new vision and era of growth and progress for Bacterin International.”

About Bacterin International Holdings

Bacterin International Holdings, Inc. (NYSE MKT: BONE) develops, manufactures and markets biologics products to domestic and international markets. Bacterin’s proprietary methods optimize the growth factors in human allografts to create the ideal stem cell scaffold to promote bone, subchondral repair and dermal growth. These products are used in a variety of applications including enhancing fusion in spine surgery, relief of back pain, promotion of bone growth in foot and ankle surgery, promotion of cranial healing following neurosurgery and subchondral repair in knee and other joint surgeries.

Bacterin’s Medical Device division develops, employs, and licenses coatings for various medical device applications. For further information, please visit www.bacterin.com.

From: http://www.dailyfinance.com/2013/04/17/bacterin-announces-updates-on-executive-leadership/